There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Costly GLP-1 drug use for weight loss has soared, study reports. ... GLP-1 drug use rose from 0.1% of the population in 2018 to 0.4% ... Moderna's new flu shot shows strong results in older adults ...

At the same time, the proportion of people using the drugs to control type 2 diabetes has declined Semaglutide is being used disproportionately by females, whites and people with obesity TUESDAY ...

TUESDAY, July 23, 2024 (HealthDay News) -- The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Many of the GLP-1 patients in their study also never reached the maximum dose. Chhabra also suspects that many people in the real world aren’t getting the supportive care and follow-up they ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.